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ABSTRACT 
Large body of evidences has indicated that the renin – angiotensin system (RAS) and its effector peptide Angiotensin II may be involved in the 
pathophysiology of stroke. Previous studies showed that preischemic RAS inhibition reduced brain injury but effects of post-ischemic RAS inhibition 
on ischemic/reperfusion injuries have not completely been elucidated. Therefore, the present study has investigated the effects of post-ischemic 
AT1 receptor blocked with candesartan treatment on cerebral infarction and motor function following transient focal cerebral ischemia in 
normotensive rats. 
Male normotensive rats were studied in three groups as sham, ischemic control and ischemic group which received candesartan (0.3mg/kg) at the 
beginning of reperfusion period. Transient focal cerebral ischemia was induced by 90 min occlusion of the left middle cerebral artery, followed by 
24 hr reperfusion. Neurological deficit score (NDS ) evaluated at the end of the reperfusion period. Total, cortical and striatal infarct volumes were 
determined using TTC staining technique. 
Animals in sham group had normal motor function and no ischemic lesions were observed in their cortical or striatal regions. MCAO in control 
ischemic group produced considerable infarctions in cortex and striatum in conjunction with severe impaired motor functions. AT1 receptor 
blocked with candesartan significantly reduced infarct volumes in the cortex and the striatum with improvement in NDS compared to control 
ischemic group. 
In conclusion, the results of the present study indicated that AT1 receptor blocked with candesartan can decrease ischemic brain injury and 
improve neurological outcome. 
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INTRODUCTION 
Ischemic stroke remains the third leading cause of invalidism and 
death in industrialized countries. Ischemic brain injury is resulted 
from a complex sequence of pathophysiological events that develop 
over time and space 1. Renin–angiotensin system (RAS) has 
traditionally been linked to the regulation of blood pressure and salt 
and water homeostasis. Beside its multiple physiological functions, 
RAS has been implicated in pathogenesis and outcome of ischemic 
injuries in vital organs such as heart 2 and kidney 3. Furthermore, it 
is suggested that RAS may contribute in stroke related pathogenic 
mechanisms and involve in the ischemic brain damage 4. It was 
showed that inhibition of the renin–angiotensin system might be 
effective not only in reducing the incidence of the stroke but also 
attenuating neuronal injury after stroke 5. It was reported that pre-
treatment with AT1 antagonists, improves neurological activity and 
reduces cerebral infarction volume in normotensive 6 and 
hypertensive rat 7. As far as the literature is concerned, only a few 
studies have addressed the effects of post-ischemic RAS inhibition 
on ischemic brain injury. Therefore, this study designed to 
investigate the influence of AT1 receptor blocked by candesartan 
post-ischemic treatment on brain injury and neurological outcome 
following transient focal cerebral ischemia in normotensive rat. 
MATERIAL AND METHODS 
Male normotensive Sprague Dawley rats (280-320 g) were obtained 
from central animal house facility of Ardabil University of Medical 
Sciences (Ardabil, Iran). All protocols of the study were approved by 
the institutional animal ethics committee of Ardabil University of 
Medical Sciences which follows the NIH guidelines for care and use 
of animals. Anesthesia made by injection of chloral hydrate 
(400mg/kg, IP). Body temperature was maintained at 37±1ºC with a 
heating feedback control system.  
Laser – Doppler Flowmetery 
Regional cerebral blood flow (rCBF) was continuously monitored 
in the cerebral cortex of the left hemisphere in the supply territory 
of middle cerebral artery (MCA) using laser Doppler flowmeter 
pencil probe(MNP100, AD instrument, Australia) 8 from 10 min 
before MCAO until 10 min after MCAO. Baseline CBF values 
measured before MCAO, were defined as 100%. MCAO was 
documented by a decrease in laser Doppler signals to lower than 
20% of baseline. 
Experimental protocol 
Effects of post-ischemic candesartan treatment on brain injury and 
neurological score were investigated in randomly divided 3 groups 
of animals as follows:  
Sham group (n=8), rats underwent the surgery at the neck region 
without being exposed to MCAO and received the vehicle, Sodium 
carbonate (SC) solution (0.1 normal) at the end of surgery.  
Control ischemic group (n=8), rats experienced brain ischemia by 90 
min MCAO followed by 24 hr reperfusion and received the vehicle 
(SC) at the beginning of reperfusion time.  
Ischemic group post-treated with Candesartan (n=8), rats 
experienced ischemia and reperfusion as same as second group and 
received candesartan (0.3 mg/kg, IV, LKT laboratories, Inc, USA) at 
the beginning of reperfusion time. 
Induction of transient focal cerebral ischemia 
Ninety minutes MCAO and 24 hr reperfusion of the left cerebral 
hemisphere carried out by intra-luminal filament method described 
by Belayev et al 9. Neurological deficits were assessed 24 hr after 
MCAO using 6 point scale: 1= Normal motor function, 2= Flexion of 
contralateral forelimb when suspended vertically by tail, 3= Circling 
when pulled with the tail to each side, 4= Spontaneous circling to 
each side, 5= Leaning to contralateral side and loss of righting reflex, 
6= No spontaneous motor activity 10. 
After NDS assessment animals were slaughtered under deep 
anesthesia and brains removed. Frontal sections of 2-mm thick slices 
were prepared using a brain matrix and stained with 
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triphenyltetrazolium chloride (TTC). After staining, the slice images 
were digitized using a Cannon camera and cerebral infarction 
volume areas were determined using computer based NIH image 
analyzer software 10, 11.  
Statistical analyses 
Values are expressed as mean±SEM. Independent T test and one-
way ANOVA with post-hoc of Duncan’s test were used for 
comparisons. Statistical significance was accepted at P<0.05. 
RESULTS 
Cerebral blood flow recording 
rCBF was reduced to less than 20% baseline in Control and 
candesartan treated ischemic groups. There was no significant 
difference in rCBF among groups during MCAO and beginning of the 
reperfusion period.  
Evaluation of neurological deficit score 
The NDS of control ischemic rats receiving vehicle was significantly 
higher than that of sham-operated rats. Post-ischemic treatment 
with candesartan significantly lowered NDS and improved motor 
function (Fig 1). 
Assessment of cerebral infarct volumes 
The sham-operated rats had no infarctions. Total infarct volume in 
ischemic rats receiving candesartan at 0.3mg/kg was significantly 
lower than control ischemic rats. Compared to control ischemic rats, 
candesartan-treated rats had significantly lower cortical and striatal 
infarct volumes (Fig 2, 3). 
 
 
Fig. 1: Neurological deficit score in sham, control and candesartan treated rats. (p<0.05 vs. control, †p<0.01 vs. sham). 
 
 
Fig. 2: Total, Cortical and striatal infarct volumes in control and candesartan treated rats. (p<0.05 vs. control). 
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Fig. 3: Representative brain slices stained with TTC in sham, control and candesartan treated rats. Ischemic regions are colored white and 
non ischemic regions are red. 
 
DISCUSSION 
Most actions of Angiotensin II are mediated through AT1 receptor 
and AT1 receptor antagonists are widely used in treatment of 
cardiovascular diseases 12. Since, these receptors contribute to 
stroke-related pathophysiological mechanisms such as 
hypertension, atherothrombosis and cardiac hypertrophy 4, it is 
possible that Angiotensin II through stimulation of AT1 receptor 
aggravates ischemic/reperfusion injuries. Previous studies showed 
that pre-ischemic blocked of AT1 receptor produces protective 
effects on ischemic brain injuries 6, 7. The results of this study 
revealed that the post-ischemic blockade of AT1 receptor reduced 
cortical and striatal infarct volumes and improved neurological 
motor deficits. These findings are in agreement with reports of other 
investigators demonstrating that AT1 receptor blockade reduced 
infarct size in transient cerebral ischemia in normotensive rats 13 or 
in hypertensive rats 14,15. In contrast, Fu et al 16 reported that 
inhibition of AT1 receptor by treatment of the animal with 
candesartan did not reduce ischemic brain injuries in the rat. This 
discrepancy is said to be due to hypotension because these 
researchers saw a significant reduction in MAP after ischemia 16. 
Profound drop in MAP hypoperfuses the ischemic area of the brain 
and prevent the reduction of cerebral infarct size 17.  
Various mechanisms might be responsible for the beneficial effects 
of AT1 receptor blockade in brain ischemia. Such effects might be 
partly attributed to their stabilization actions on the impaired 
cerebrovascular autoregulation in penumbra 18-20. In addition, anti-
apoptotic mechanisms may help the manifestation of protective 
effects of AT1 receptors blockade 21. It was suggested that AT1 
receptor activation initiates proapoptotic stimuli in neuronal cells. 
Thus, anti-apoptotic effects of AT1 receptor blockade may have 
beneficial effects on ischemic brain injury 22. Oxidative stress is 
known to be responsible for molecular and cellular tissue damage 
mechanisms in wide range of diseases 23 including stroke. The 
beneficial effects of AT1 receptor blockade might also be 
attributed to the reduction of ROS production. The activation of 
AT1 receptor results in the production of superoxide, whereas its 
blockade was associated with the reduction of superoxide 24 and 
peroxynitrite 25.  
CONCLUSION  
In conclusion, the results of this study demonstrate that post-
ischemic inhibition of the RAS by an AT1 receptor antagonist, 
candesartan reduces cerebral infarction volume, and improve 
neurological motor activity in normotensive rats exposed to 
transient MCA occlusion. 
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